Covid Reference

Page 48

48

|

CovidReference.com

(around 260 million people) would have contracted the disease. Of those, 2,2 million Americans would have died, including 4% to 8% of those over age 70 (Ferguson 2020). In Germany alone, the SARS-CoV-2 pandemic could have resulted in 730.000 deaths (Barbarossa 2020) with 500.000 deaths each in France, Italy, Spain and the UK.

The 2020 Lockdowns Fortunately, the world has been spared from a freely circulating SARS-CoV-2. If humanity can change the climate, why shouldn’t we be able to change the course of a pandemic? Although economists warned that unemployment could surpass the levels reached during the Great Depression in the 1930s, at first, almost all governments considered saving hundreds of thousands lives more important than avoiding a massive economic recession. First in China, six weeks later in Italy and another a week later in most Western European countries, and later in the US and in many other countries in the world, unprecedented experiments of gigantic dimensions were started: ordering entire regions or the whole nation to lockdown. By the first week of April, 4 billion people worldwide were under some form of lockdown — more than half of the world’s population. Lockdowns in Europe were generally less strict than in China, allowing the continuation of essential services and industries and the circulation of people when justified. People were generally compliant to mandatory stay-at-home orders, even in the US. Based on location data from mobile devices, in 97,6% of US counties these orders were associated with decreased median population movement (Moreland 2020). Lockdowns were generally also well accepted. During the week of May 5–12, 2020, a survey among 2402 adults In New York City and Los Angeles found widespread support of stay-at-home orders and non-essential business closures, and a high degree of adherence to COVID-19 mitigation guidelines (Czeisler 2020). Lockdowns were also successful in slowing down the pandemic. In New York City, SARS-CoV-2 prevalence varied substantially between boroughs between 22 March and 3 May 2020 (for example, Manhattan: 11,3%; South Queens: 26,0%). These differences in prevalence correlate with antecedent reductions in commuting-style mobility between the boroughs. Prevalence was lowest in boroughs with the greatest reductions in morning movements out of and evening movements into the borough (Kissler 2020). According to one study, between 12 and 15 million individuals in Europe had been infected with SARSCoV-2 by May 4th, representing only between 3,2% and 4,0% of the population (Flaxman June 2020). Projected percentages of the total population infected ranged from a low of 0,76% in Austria to a high of 8,0% in Belgium. In South Kamps – Hoffmann


Turn static files into dynamic content formats.

Create a flipbook

Articles inside

References

1hr
pages 497-554

Management

10min
pages 491-496

Diagnosis and classification

11min
pages 484-490

Transplantation

4min
pages 472-473

Transmission

4min
pages 482-483

Pathophysiology and immunopathology

4min
pages 480-481

Natural course and risk factors for complications

2min
page 479

Epidemiology of COVID-19 in children

2min
page 478

Cancer

8min
pages 468-471

Immunosuppression (other than HIV

3min
pages 466-467

HIV infection

6min
pages 463-465

COPD and smoking

4min
pages 461-462

Hypertension and cardiovascular co-morbidities

14min
pages 452-458

Diabetes mellitus

4min
pages 459-460

References

6min
pages 447-451

Special situations in severe COVID-19

3min
pages 445-446

References

25min
pages 429-440

Spotlight: The situation in a German COVID-19 hospital

4min
pages 443-444

Outlook and Recommendations

1min
page 428

4. Immunomodulators

19min
pages 415-424

Other treatments for COVID-19 (with unknown or unproven mechanisms of action

5min
pages 425-427

3. Monoclonal Antibodies and Convalescent Plasma

13min
pages 408-414

2. Various antiviral agents

5min
pages 405-407

1. Inhibitors of the viral RNA synthesis

11min
pages 399-404

Monitoring, treatment options

3min
pages 391-392

Studies with objectifiable tests

3min
pages 389-390

Reactivations, reinfections

2min
page 366

Outcome

27min
pages 352-365

Clinical classification

1min
page 351

Laboratory findings

6min
pages 347-350

References

21min
pages 324-332

Asymptomatic cases

4min
pages 334-335

Radiology

6min
pages 321-323

Incubation period

1min
page 333

Symptoms

21min
pages 336-346

Diagnosis

36min
pages 303-320

References

55min
pages 277-302

Outlook

5min
pages 272-276

Single Vaccines

24min
pages 247-261

Coming vaccines

8min
pages 267-271

Special Topics

9min
pages 241-246

Approved Vaccines

2min
pages 223-224

References

21min
pages 211-222

Outlook

1min
page 210

Transmission

1min
page 187

Epidemiology

11min
pages 175-186

Summary – 13 February

1min
page 173

Genomic Structure and Variation

4min
pages 164-166

References

8min
pages 167-172

Origin and Evolution

4min
pages 158-159

Introduction

1min
page 174

History

4min
pages 154-155

References

20min
pages 136-152

Conclusion

1min
page 135

Introduction

31min
pages 117-133

Containment or mitigation of COVID-19?

1min
page 134

References

40min
pages 99-116

Outlook

1min
page 98

Prevention

3min
pages 96-97

End of Quarantine

1min
page 95

Transmission Event

26min
pages 82-94

References

31min
pages 54-68

Summary

1min
page 69

Routes of Transmission

16min
pages 73-81

Outlook

3min
pages 52-53

The 2020 Lockdowns

7min
pages 48-51

Person-to-person transmission

2min
page 72

Special Aspects of the Pandemic

15min
pages 38-46

The SARS-CoV-2 pandemic: Past and Future

2min
page 47
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.